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Conjunctival keratoacanthoma is a rare disease which is believed 
to be a low-grade form of squamous cell carcinoma (SCC). 
Although conjunctival keratoacanthoma was primarily described 
almost 60 years ago, only few cases have been described in the 
English literature and its diagnosis and treatment guidelines are 
still controversial. Almost all suggested treatment options have 
been surgical methods and non-invasive methods have rarely been 
examined in treatment of this disease. Here we report an interesting 
case of conjunctival keratoacanthoma which was treated with 
topical Interferon-alpha2b.
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Introduction
Keratoacanthoma (KA) is a common tumoral 
lesion which arises from the pilosebaceous 
glands of hair follicles and is believed to be 
a low grade form of squamous cell carcinoma 
(SCC) 1. Keratoacanthoma most commonly 
originates in sun-exposed, hair-bearing areas 
of skin and only rarely happen on mucosal 
surfaces 1. Conjunctival keratoacanthoma 
is a rare disease with only few cases 
described in the English literature. Almost all 
suggested treatment options for conjunctival 
keratoacanthoma have been surgical methods 
and non-invasive methods have rarely been 
examined in treatment of this disease. Here 
we report an interesting case of conjunctival 
keratoacanthoma which was treated with 
topical Interferon-alpha2b.
Case report
A 33-year-old male presented to our ocular 
surface clinic, complaining of a rapidly 
growing mass on his left eye since two weeks 
ago. The patient was a welder, had no previous 
history of ocular trauma or surgery, and also 
no history of any ocular or systemic diseases. 
Best corrected visual acuity of both eyes was 
10/10. On slit lamp examination, a protruding 
nodular mass was evident in nasal bulbar 
conjunctiva, encroaching to the limbus. The 
conjunctival mass was 5 × 5 mm in size, was 
congested with surrounding dilated vessels, 
and had a hyperkeratotic surface (Figure 1A). 
According to the clinical picture and the time 
course of the lesion growth, the patient was 
diagnosed with conjunctival keratoacanthoma. 
Treatment with topical Interferon-alpha2b 
(IFN α-2b), 3 mIU four times per day, was 
started and patient was followed for signs of 
improvement every 2 weeks. After one month 
of treatment the lesion started to regress 
(Figure 1B) and 2 months after starting the 
Interferon treatment near complete resolution 
of the lesion was observed (Figure 1C). 
Treatment was continued for another 2 months 
after resolution. No sign of relapse was seen 6 
months after the first visit (Figure 1D). 
Discussion  
Keratoacanthoma presents as a dome shaped 
nodule with a central keratin-filled crater 2. 
Almost all previously reported conjunctival 
keratoacanthomas have been located on the 
temporal bulbar conjunctiva, adjacent to the 
limbus, within the palpebral fissure 3. The 
present case was unusual in that it occurred 
in nasal bulbar conjunctiva. An exclusive 
feature of keratoacanthoma is its unusual 
natural course which includes 3 phases: 
proliferative phase characterized by a rapid 
growth, stabilization phase (well-developed 
mature lesion) and involutional phase in 
which the lesion undergoes spontaneous 
regression 4. It takes about 9 weeks for the 
lesion to present and about 27 weeks to 
disappear 5. The main differential diagnosis 
of keratoacanthoma is SCC, which develops 
more slowly than keratoacanthoma, is less 
well demarcated, and lacks the central keratin 
filled crater 3. Because of the unpredictable 
behavior of keratoacanthoma and difficulty to 
differentiate it from SCC, both clinically and 
histopathologically; there is no consensus or 
guideline for the best management protocol. 
There are several treatment choices such 
as surgical excision, topical therapy with 
5-fluorouracil (5-FU) or Imiquimod, 
and intralesional therapy with 5-FU or 
methotrexate 6. 
In 2014, Oellers et al., 6 reported a case of 
conjunctival keratoacanthoma which was 
treated with surgical excision followed by 
topical Interferon-alpha2b four times per day 
for 2 months. 
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It is not always possible to differentiate 
keratoacanthoma from SCC or be sure that 
SCC will not evolve from a keratoacanthoma 
lesion. That is why most previously reported 
conjunctival keratoacanthomas have been 
managed by surgical excision. In the 
management of ocular surface squamous 
neoplasia (OSSN) including SCC, clinical 
practice patterns are evolving from wide local 
excision toward the less invasive use of topical 
chemotherapy drugs like Interferon-alpha2b 
as monotherapy alone or as adjuvant drugs 7. 
We used topical Interferon-alpha2b for 
treatment of keratoacanthoma as a non-
invasive method. One of the drawbacks of this 
method is that without surgical excision we 
could not have histopathologic confirmation 
of the diagnosis. However, considering the 
clinical features and the rapid growth pattern 
the diagnosis could be made with high certainty. 
Another limitation is that the natural course of 
keratoacanthoma includes final regression after 
initial growth and therefore it is not possible 
to differentiate the natural course from the 
treatment effect. However, considering that 
SCC is an important differential diagnosis, 
observation alone and waiting for spontaneous 
regression of the lesion is not recommended.
Conclusion
Here, we introduced a rare case of conjunctival 
keratoacanthoma along with a novel treatment 
method. Topical Interferon-alpha2b was used 
as a substitute for the invasive wide local 
surgical excision and was effective in the 
management of conjunctival keratoacanthoma. 
This treatment method should be investigated 
in more subjects with a longer follow up 
Figure 1: (A) Before treatment with IFN α-2b, (B) One month after starting treatment 
with IFN α-2b, (C) Two months after starting treatment with Interferon-alpha2b, (D) 
Six months after the first visit
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period before suggesting it as an alternative 
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